pheon therapeutics ltd

Live EstablishedSmall

pheon therapeutics ltd Company Information

Share PHEON THERAPEUTICS LTD

Company Number

09677410

Shareholders

research corporation technologies inc

atlas venture fund xii l p

View All

Group Structure

View All

Industry

Research and experimental development on biotechnology

 

Registered Address

innovation house innovation way, discovery park, sandwich, kent, CT13 9FF

pheon therapeutics ltd Estimated Valuation

£2m

Pomanda estimates the enterprise value of PHEON THERAPEUTICS LTD at £2m based on a Turnover of £1.5m and 1.36x industry multiple (adjusted for size and gross margin).

pheon therapeutics ltd Estimated Valuation

£0

Pomanda estimates the enterprise value of PHEON THERAPEUTICS LTD at £0 based on an EBITDA of £-21.7m and a 5.35x industry multiple (adjusted for size and gross margin).

pheon therapeutics ltd Estimated Valuation

£31.3m

Pomanda estimates the enterprise value of PHEON THERAPEUTICS LTD at £31.3m based on Net Assets of £17.5m and 1.79x industry multiple (adjusted for liquidity).

Edit your figures and get a professional valuation report.

Pheon Therapeutics Ltd Overview

Pheon Therapeutics Ltd is a live company located in sandwich, CT13 9FF with a Companies House number of 09677410. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in July 2015, it's largest shareholder is research corporation technologies inc with a 19.3% stake. Pheon Therapeutics Ltd is a established, small sized company, Pomanda has estimated its turnover at £1.5m with unknown growth in recent years.

View Sample
View Sample
View Sample

Upgrade for unlimited company reports & a free credit check

Pheon Therapeutics Ltd Health Check

Pomanda's financial health check has awarded Pheon Therapeutics Ltd a 4.5 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 3 areas for improvement. Company Health Check FAQs

Health Check Image
Health Rating4.5out of 5
positive_score

4 Strong

positive_score

2 Regular

positive_score

3 Weak

size

Size

annual sales of £1.5m, make it smaller than the average company (£3.5m)

£1.5m - Pheon Therapeutics Ltd

£3.5m - Industry AVG

growth

Growth

There is insufficient data available for this Key Performance Indicator!

- - Pheon Therapeutics Ltd

- - Industry AVG

production

Production

with a gross margin of 54.5%, this company has a comparable cost of product (54.5%)

54.5% - Pheon Therapeutics Ltd

54.5% - Industry AVG

profitability

Profitability

an operating margin of -1468.4% make it less profitable than the average company (-7.8%)

-1468.4% - Pheon Therapeutics Ltd

-7.8% - Industry AVG

employees

Employees

with 9 employees, this is below the industry average (46)

9 - Pheon Therapeutics Ltd

46 - Industry AVG

paystructure

Pay Structure

on an average salary of £79.9k, the company has an equivalent pay structure (£79.9k)

£79.9k - Pheon Therapeutics Ltd

£79.9k - Industry AVG

efficiency

Efficiency

resulting in sales per employee of £164.1k, this is more efficient (£124.5k)

£164.1k - Pheon Therapeutics Ltd

£124.5k - Industry AVG

debtordays

Debtor Days

There is insufficient data available for this Key Performance Indicator!

- - Pheon Therapeutics Ltd

- - Industry AVG

creditordays

Creditor Days

its suppliers are paid after 385 days, this is slower than average (53 days)

385 days - Pheon Therapeutics Ltd

53 days - Industry AVG

stockdays

Stock Days

There is insufficient data available for this Key Performance Indicator!

- - Pheon Therapeutics Ltd

- - Industry AVG

cashbalance

Cash Balance

has cash to cover current liabilities for 540 weeks, this is more cash available to meet short term requirements (34 weeks)

540 weeks - Pheon Therapeutics Ltd

34 weeks - Industry AVG

debtlevel

Debt Level

it has a ratio of liabilities to total assets of 8.5%, this is a lower level of debt than the average (50.9%)

8.5% - Pheon Therapeutics Ltd

50.9% - Industry AVG

PHEON THERAPEUTICS LTD financials

EXPORTms excel logo

Pheon Therapeutics Ltd's latest turnover from March 2024 is estimated at £1.5 million and the company has net assets of £17.5 million. According to their latest financial statements, Pheon Therapeutics Ltd has 9 employees and maintains cash reserves of £16.8 million as reported in the balance sheet.

Data source: Companies HousePomanda Estimates

Mar 2024Mar 2023Mar 2022Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
Turnover1,477,1731,079,561607,894453,903631,634735,418858,461569,833
Other Income Or Grants
Cost Of Sales672,833498,270311,922217,790312,848357,393430,923298,196
Gross Profit804,340581,290295,972236,112318,787378,025427,537271,638
Admin Expenses22,495,82510,988,0688,852,9221,561,8721,861,1641,745,5791,261,9871,106,030
Operating Profit-21,691,485-10,406,778-8,556,950-1,325,760-1,542,377-1,367,554-834,450-834,392
Interest Payable
Interest Receivable791,697783,95488,1335464,4721,8693,5181,537
Pre-Tax Profit-20,899,788-9,622,824-8,468,817-1,325,214-1,537,905-1,365,685-830,932-832,855
Tax
Profit After Tax-20,899,788-9,622,824-8,468,817-1,325,214-1,537,905-1,365,685-830,932-832,855
Dividends Paid
Retained Profit-20,899,788-9,622,824-8,468,817-1,325,214-1,537,905-1,365,685-830,932-832,855
Employee Costs718,654651,587437,879563,139615,000609,294608,415461,573
Number Of Employees996899108
EBITDA*-21,683,553-10,376,207-8,477,141-1,251,748-1,469,779-1,303,549-803,862-827,441

* Earnings Before Interest, Tax, Depreciation and Amortisation

Mar 2024Mar 2023Mar 2022Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
Tangible Assets96120,04345,214120,739197,287236,290239,579114,819
Intangible Assets179157235313
Investments & Other
Debtors (Due After 1 year)
Total Fixed Assets96120,04345,214120,740197,366236,447239,814115,132
Stock & work in progress
Trade Debtors35,00040,0005,0003,840
Group Debtors44,733
Misc Debtors2,311,5842,406,449110,708146,401144,536377,672355,169190,380
Cash16,769,98513,389,91123,502,060221,049871,647321,002177,3981,229,762
misc current assets
total current assets19,081,56915,876,09323,652,768372,4501,020,023698,674532,5671,420,142
total assets19,082,53015,896,13623,697,982493,1901,217,389935,121772,3811,535,274
Bank overdraft
Bank loan
Trade Creditors 710,500924,318252,04951,430238,58449,28280,97823,773
Group/Directors Accounts179,082
other short term finances
hp & lease commitments
other current liabilities722,859908,794116,38275,45171,41374,94028,35221,173
total current liabilities1,612,4411,833,112368,431126,881309,997124,222109,33044,946
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities2,458,7181,641,041
provisions33,55240,19626,67423,026
total long term liabilities2,458,7181,674,59340,19626,67423,026
total liabilities1,612,4411,833,112368,4312,585,5991,984,590164,418136,00467,972
net assets17,470,08914,063,02423,329,551-2,092,409-767,201770,703636,3771,467,302
total shareholders funds17,470,08914,063,02423,329,551-2,092,409-767,201770,703636,3771,467,302
Mar 2024Mar 2023Mar 2022Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
Operating Activities
Operating Profit-21,691,485-10,406,778-8,556,950-1,325,760-1,542,377-1,367,554-834,450-834,392
Depreciation7,93230,57179,80873,93472,52063,92730,5106,873
Amortisation17878787878
Tax
Stock
Debtors-174,5982,335,474150,7083,025-229,29622,503164,789190,380
Creditors-213,818672,269252,049-187,154189,302-31,69657,20523,773
Accruals and Deferred Income-185,935792,412116,3824,038-3,52746,5887,17921,173
Deferred Taxes & Provisions-33,552-6,64413,5223,64823,026
Cash flow from operations-21,908,708-11,247,000-8,259,418-1,471,441-1,061,352-1,297,638-900,619-949,849
Investing Activities
capital expenditure11,150-5,400-125,0232,614-33,517-60,638-155,270-122,083
Change in Investments
cash flow from investments11,150-5,400-125,0232,614-33,517-60,638-155,270-122,083
Financing Activities
Bank loans
Group/Directors Accounts179,082
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities817,6771,641,041
share issue24,306,853356,29731,798,368611,500,01172,300,157
interest791,697783,95488,1335464,4721,8693,5181,537
cash flow from financing25,277,6321,140,25131,886,501818,2291,645,5141,501,8803,5252,301,694
cash and cash equivalents
cash3,380,074-10,112,14923,502,060-650,598550,645143,604-1,052,3641,229,762
overdraft
change in cash3,380,074-10,112,14923,502,060-650,598550,645143,604-1,052,3641,229,762

pheon therapeutics ltd Credit Report and Business Information

Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for pheon therapeutics ltd. Get real-time insights into pheon therapeutics ltd's credit score, group structure and payment trends.

From as little as £6.99

This will not impact your credit rating!

View Credit Report Sample

Pheon Therapeutics Ltd Competitor Analysis

competitor_analysis_table_img

Perform a competitor analysis for pheon therapeutics ltd by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other small companies, companies in CT13 area or any other competitors across 12 key performance metrics.

pheon therapeutics ltd Ownership

PHEON THERAPEUTICS LTD group structure

Pheon Therapeutics Ltd has no subsidiary companies.

Ultimate parent company

PHEON THERAPEUTICS LTD

09677410

PHEON THERAPEUTICS LTD Shareholders

research corporation technologies inc 19.29%
atlas venture fund xii l p 14.01%
forbion capital fund v cooperatief u.a 14.01%
tcg crossover fund ii l.p 7.23%
hostplus pty ltd 5.13%
forbion capital fund v cooperatief u.a. 4.44%
atlas venture fund xii lp 4.44%
cyrus mozayeni 4.43%
biotechnology value fund l.p 3.61%
biotechnology value fund ii l.p 3.13%

pheon therapeutics ltd directors

Pheon Therapeutics Ltd currently has 9 directors. The longest serving directors include Mr Shaun Kirkpatrick (Sep 2015) and President Michael Gladstone (Mar 2022).

officercountryagestartendrole
Mr Shaun KirkpatrickUnited Kingdom56 years Sep 2015- Director
President Michael GladstoneUnited States38 years Mar 2022- Director
Dr Rogier RooswinkelNetherlands41 years Mar 2022- Director
Mr Jonathan TobinUnited Kingdom42 years Mar 2022- Director
Dr Rogier RooswinkelNetherlands41 years Mar 2022- Director
Mr Jeffery AlbersUnited Kingdom53 years Jan 2023- Director
Dr Cyrus MozayeniUnited States50 years Jul 2023- Director
Mr Cariad ChesterUnited States33 years Apr 2024- Director
Mr Enoch KariukiUnited Kingdom43 years Sep 2024- Director

P&L

March 2024

turnover

1.5m

+37%

operating profit

-21.7m

0%

gross margin

54.5%

+1.13%

turnover

Turnover, or revenue, is the amount of sales generated by a company within the financial year.

Balance Sheet

March 2024

net assets

17.5m

+0.24%

total assets

19.1m

+0.2%

cash

16.8m

+0.25%

net assets

Total assets minus all liabilities

pheon therapeutics ltd company details

company number

09677410

Type

Private limited with Share Capital

industry

72110 - Research and experimental development on biotechnology

incorporation date

July 2015

age

10

incorporated

UK

ultimate parent company

None

accounts

Total Exemption Full

last accounts submitted

March 2024

previous names

femtogenix ltd (August 2022)

accountant

KRESTON REEVES LLP

auditor

-

address

innovation house innovation way, discovery park, sandwich, kent, CT13 9FF

Bank

-

Legal Advisor

-

pheon therapeutics ltd Charges & Mortgages

A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.

We did not find charges/mortgages relating to pheon therapeutics ltd.

pheon therapeutics ltd Capital Raised & Share Issues BETA

When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.

Click to start generating capital raising & share issue transactions for PHEON THERAPEUTICS LTD. This can take several minutes, an email will notify you when this has completed.

pheon therapeutics ltd Companies House Filings - See Documents

datedescriptionview/download